Study guide
6.2 Sedation, Analgesia & Neuromuscular Blockade in Transport
Neonatal Pediatric Transport C-NPT
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The C-NPT Exam
About the C-NPT Exam: 2026 Format, Eligibility & Content Outline
2 Chapter 1: Transport Systems, Regulatory Framework & Legal Issues
1.1 Transport System Architecture, Accreditation (CAMTS) & Dispatch Triage 1.2 Regulatory & Legal Mandates: EMTALA, HIPAA, Consent & Documentation 1.3 Medical Direction, Scope of Practice & Ethical Considerations
3 Chapter 2: Safety, Communication, Crew Resource Management & Transport Environment
2.1 Crew Resource Management (CRM), Situational Awareness & Sterile Cockpit 2.2 Aircraft & Ground Ambulance Operations, Landing Zones & Vehicle Dynamics 2.3 Environmental Hazards, Weather Minimums & In-Flight Emergency Procedures 2.4 Communication in Transport: Peer Handoffs, Age-Appropriate Care, Families & Crew Stressors 2.5 Infection Control, PPE, Scene Safety & Disaster/Evacuation Planning
4 Chapter 3: Flight Physiology & Environmental Stressors
3.1 Physical Gas Laws & Transport Implications (Boyle, Dalton, Charles, Henry, Graham) 3.2 Altitude Hypoxia, Barometric Pressure Changes & Dysbarism 3.3 Acceleration Forces (G-forces), Vibration & Acoustic Stress in Transit 3.4 Thermoregulation Physics & Neutral Thermal Environment in Transit
5 Chapter 4: Invasive Procedures & Transport Monitoring
4.1 Advanced Airway Management & Endotracheal Intubation in Transit 4.2 Pleural Decompression (Needle Thoracostomy & Chest Tube Management) 4.3 Vascular Access: Umbilical Lines (UAC/UVC), Intraosseous (IO) & Arterial Lines
6 Chapter 5: Transport Equipment, Respiratory Physiology & Mechanical Ventilation
5.1 Transport Incubators (Isolettes), Thermal Control & Electrical/Gas Power Systems 5.2 Portable Ventilators & Modes (PC, VC, PRVC, High Frequency) 5.3 Gas Cylinder Duration Calculations, Oxygen Delivery & Inhaled Nitric Oxide (iNO) 5.4 Respiratory Physiology: Acid-Base Balance, Oxygenation, Lung Mechanics & Troubleshooting
7 Chapter 6: Transport Pharmacology, Resuscitation, Fluids & Electrolytes
6.1 Vasoactive Infusions & Inotropes (Epinephrine, Dopamine, Dobutamine, Milrinone) 6.2 Sedation, Analgesia & Neuromuscular Blockade in Transport 6.3 Prostaglandin E1 (Alprostadil) & Surfactant Replacement Therapy 6.4 Resuscitation Protocols (NRP, PALS) & Shock Fluid Resuscitation 6.5 Antimicrobial Pharmacology in Neonatal & Pediatric Transport 6.6 Post-Resuscitation Care, Defibrillation & Cardioversion in Transit, ECMO Indications & the Transport-vs-Stay Decision 6.7 Fluid & Electrolyte Therapy Across the Ages: Maintenance, Dehydration, Fluid Overload & Electrolyte Emergencies
8 Chapter 7: Neonatal Respiratory Pathologies & Management
7.1 Respiratory Distress Syndrome (RDS) & Surfactant Deficiency 7.2 Meconium Aspiration Syndrome (MAS) & Persistent Pulmonary Hypertension (PPHN) 7.3 Transient Tachypnea (TTN), Neonatal Pneumothorax & Congenital Diaphragmatic Hernia (CDH) 7.4 Neonatal Upper Airway Anomalies, Aspiration, Pneumonia, Chronic Lung Disease & Respiratory Failure
9 Chapter 8: Neonatal Cardiovascular Critical Care
8.1 Ductal-Dependent Cyanotic Congenital Heart Defects (TGA, TOF, Tricuspid Atresia) 8.2 Ductal-Dependent Systemic Blood Flow Lesions (HLHS, Coarctation, Interrupted Arch) 8.3 Neonatal Arrhythmias, Cardiogenic Shock & Post-Resuscitation Care 8.4 Acyanotic Congenital Heart Lesions, Patent Ductus Arteriosus, Obstructed TAPVR & Neonatal Heart Failure
10 Chapter 9: Neonatal Neurological & Metabolic Crises
9.1 Hypoxic-Ischemic Encephalopathy (HIE) & Passive/Active Therapeutic Hypothermia 9.2 Neonatal Seizures & Intraventricular Hemorrhage (IVH) 9.3 Neonatal Hypoglycemia, Electrolyte Derangements & Hyperbilirubinemia 9.4 Subgaleal Hemorrhage, Neonatal Sepsis & Meningitis, and Perinatal Substance Exposure (NOWS)
11 Chapter 10: Neonatal Surgical Emergencies, Neural Tube Defects & ELBW Care
10.1 Abdominal Wall Defects (Gastroschisis vs. Omphalocele) & TEF/Esophageal Atresia 10.2 Necrotizing Enterocolitis (NEC), Malrotation with Volvulus & Intestinal Obstruction 10.3 Care of the Extremely Low Birth Weight (ELBW) Infant (<1000g) in Transit 10.4 Neural Tube Defects: Myelomeningocele, Encephalocele & Transport of the Newborn With an Open Spinal Defect
12 Chapter 11: Pediatric Respiratory Emergencies
11.1 Acute Upper Airway Obstruction (Croup, Epiglottitis, Bacterial Tracheitis, Foreign Body) 11.2 Lower Airway Crises: Status Asthmaticus & Severe Bronchiolitis 11.3 Pediatric Acute Respiratory Distress Syndrome (PARDS) & Severe Pneumonia
13 Chapter 12: Pediatric Shock & Cardiovascular Crises
12.1 Pathophysiology & Transport Management of Pediatric Septic Shock 12.2 Hypovolemic, Cardiogenic & Anaphylactic Shock in Children 12.3 Pediatric Cardiac Emergencies: SVT, Ventricular Arrhythmias & Myocarditis 12.4 Pediatric Cardiovascular Crises: Palliated Congenital Heart Disease, Pulmonary Hypertensive Crisis, Pericarditis & Tamponade, Hypertensive Emergency & Anterior Mediastinal Mass
14 Chapter 13: Pediatric Neurological Emergencies & Trauma
13.1 Status Epilepticus, Altered Mental Status & Meningitis/Encephalitis 13.2 Pediatric Traumatic Brain Injury (TBI) & Increased Intracranial Pressure (ICP) 13.3 Blunt/Penetrating Trauma, Spinal Motion Restriction & Thermal Burns 13.4 Non-Accidental Trauma, Smoke Inhalation (Carbon Monoxide & Cyanide) & Heat Illness
15 Chapter 14: Pediatric Toxicological, Environmental & Endocrine Emergencies
14.1 Common Pediatric Toxic Ingestions, Poisonings & Antidotes 14.2 Diabetic Ketoacidosis (DKA) & Environmental Emergencies (Submersion, Hypothermia) 14.3 Button Battery & Foreign-Body Ingestions, Bites & Envenomations, and Hazardous-Material Exposures
16 Chapter 15: Pediatric Metabolic & Hematologic Emergencies
15.1 Anemia, Sickle Cell Disease, Coagulopathies & Blood Product Administration 15.2 Oncologic Emergencies, Acute Kidney Injury & Pediatric Electrolyte Crises
6.2 Sedation, Analgesia & Neuromuscular Blockade in Transport
Key Takeaways Explain This Topic AI
Rapid Sequence Intubation (RSI) in critical care transport requires hemodynamic optimization, tailored induction, and a plan for bradycardia; AHA PALS guidance says atropine premedication is reasonable when bradycardia risk is higher (for example, with succinylcholine), at 0.02 mg/kg with no minimum dose.
Ketamine (1-2 mg/kg IV) is the ideal induction agent for pediatric patients in septic shock or status asthmaticus because it releases endogenous catecholamines, preserves systemic vascular resistance, and produces direct bronchial smooth muscle dilation.
Rapid intravenous administration of fentanyl (>3-5 mcg/kg rapid push) can precipitate wooden chest syndrome (rigid chest wall and vocal cord closure) that prevents bag-mask ventilation, requiring immediate rescue paralysis with rocuronium or reversal with naloxone.
Succinylcholine (1.5-2.0 mg/kg in infants/children) provides rapid depolarizing neuromuscular blockade but is strictly contraindicated in acute burns >24-48 hours, major crush injury, denervating neuromuscular disease, and suspected malignant hyperthermia due to fatal hyperkalemia.
Neuromuscular blocking agents possess zero analgesic or hypnotic properties; transport clinicians must guarantee continuous deep sedation and analgesia before and during paralysis, with sugammadex or neostigmine/glycopyrrolate immediately available for non-depolarizing block reversal.
Last updated: September 2026
Sedation, Analgesia & Neuromuscular Blockade in Transport
Airway management and patient comfort during neonatal and pediatric critical care transport represent some of the highest-acuity interventions encountered in mobile intensive care. The physiological stress of transport—including vehicular vibration, gravitational acceleration forces, loud ambient noise, and thermal instability—exacerbates pain, agitation, and oxygen consumption. Transport clinicians must possess nuanced pharmacological mastery of induction agents, continuous sedatives, analgesics, and neuromuscular blockers, ensuring hemodynamic stability while avoiding catastrophic complications.
Transport Rapid Sequence Intubation (RSI) Protocols
Rapid Sequence Intubation in the transport environment differs markedly from controlled operating room induction. The patient often has severe physiological derangements (hypoxemia, hypovolemia, elevated intracranial pressure, or reactive airway disease), and the physical space inside an aircraft or ambulance severely restricts maneuverability.
The 7 Ps of Transport RSI
Preparation: Equipment verification (video laryngoscope, backup supraglottic airway, bougie, suction), medication calculation, and smart pump setup.
Preoxygenation: 3 minutes of high-flow 100% FiO 2 \text{FiO}_2 FiO 2 via non-rebreather or CPAP/BiPAP; avoid aggressive positive pressure ventilation if possible to minimize gastric insufflation.
Premedication: Administer vagolytic or sympathetic blunting agents 1–2 minutes prior to induction.
Paralysis with Induction: Immediate sequential administration of a potent sedative-hypnotic followed immediately by a rapid-acting neuromuscular blocker.
Positioning & Protection: Neutral airway alignment, ramped sniffing position for older children, shoulder roll for neonates, and passive oxygenation.
Placement with Proof: Visualized tube passage through the vocal cords, followed by mandatory continuous waveform capnography ( EtCO 2 \text{EtCO}_2 EtCO 2 ) and bilateral auscultation.
Post-intubation Management: Secure tube at calculated depth, establish mechanical ventilation, and initiate continuous maintenance sedation.
Premedication Pharmacodynamics: Atropine & Glycopyrrolate
Neonates and young infants are predisposed to severe, life-threatening vagal bradycardia during airway manipulation. Parasympathetic tone predominates in early life, and direct stimulation of the laryngeal and pharyngeal mucosa by a laryngoscope blade triggers profound bradycardia. Furthermore, succinylcholine stimulates muscarinic receptors in the SA node, which can cause bradycardia or sinus arrest, especially with repeated doses.
Atropine Sulfate (0.02 mg/kg IV/IO): Competitive muscarinic acetylcholine receptor antagonist. It blocks vagal afferents, increases SA nodal firing, and dries airway secretions.
Dose for Premedication: Since the 2015 update, AHA PALS guidance states that 0.02 mg/kg with no minimum dose may be considered when atropine is used as premedication for emergency intubation. The old 0.1 mg minimum came from concern about paradoxical bradycardia with tiny doses, but it can overdose small infants several-fold. The PALS bradycardia algorithm, a different indication, still lists a 0.1 mg minimum and a 0.5 mg maximum single dose.
When to Use It: Atropine is not required for every intubation. PALS considers it reasonable when bradycardia risk is higher, such as with succinylcholine (especially repeated doses) or in young infants with strong vagal responses. Many transport programs still premedicate infants by protocol.
Glycopyrrolate (0.005–0.01 mg/kg, max 0.2 mg): A synthetic quaternary ammonium anticholinergic. Because it does not cross the blood-brain barrier, it produces potent antisialagogue (secretory drying) effects without causing central anticholinergic sedation or pupillary changes, preserving neurological assessment.
Induction Pharmacology: Matching the Agent to Patient Physiology
Induction Agent IV/IO Dose Onset / Duration Hemodynamic & Organ System Effects Transport Clinical Indications & Risks
Ketamine 1.0 – 2.0 mg/kg 30–60 sec / 15–30 min Stimulates central sympathetic outflow (releases endogenous catecholamines); preserves SVR, heart rate, and MAP; direct bronchodilator. First-line in septic shock, hypovolemia, and status asthmaticus. Caution in catecholamine-depleted shock (can reveal unmasked direct myocardial depression).
Etomidate 0.2 – 0.3 mg/kg 15–30 sec / 5–15 min Minimal hemodynamic fluctuation; preserves cerebral perfusion pressure; decreases cerebral blood flow and ICP. Ideal for traumatic brain injury and normotensive critical airway. Blocks 11-beta-hydroxylase, causing transient adrenal suppression (relative contraindication in sepsis).
Midazolam 0.1 – 0.2 mg/kg 1–3 min / 30–60 min GABA-A agonist; potent amnesic and anxiolytic; causes peripheral vasodilation and myocardial depression. Safe for hemodynamically stable patients with status epilepticus. Causes severe hypotension if given rapidly to hypovolemic or septic children.
Propofol 1.0 – 2.5 mg/kg 15–30 sec / 5–10 min Potent GABA agonist; profound reduction in SVR, MAP, and myocardial contractility; blunts airway reflexes. Contraindicated in shock, trauma, or sepsis due to acute cardiovascular collapse. Reserved for hemodynamically robust pediatric patients.
Fentanyl 1.0 – 2.0 mcg/kg 1–2 min / 30–60 min Pure synthetic mu-opioid agonist; minimal histamine release; excellent cardiovascular stability. Ideal for cardiogenic shock, cyanotic CHD, and elevated ICP. Risk of acute chest wall rigidity if pushed rapidly.
Neuromuscular Blocking Agents (NMBAs): Depolarizing vs. Non-Depolarizing
Neuromuscular blockers eliminate patient movement, prevent fighting the ventilator, ablate vocal cord motion during intubation, and eliminate shivering during therapeutic hypothermia.
Succinylcholine (1.5–2.0 mg/kg IV/IO, 3.0–4.0 mg/kg IM)
A depolarizing neuromuscular blocker that binds to nicotinic acetylcholine receptors at the motor endplate, triggering persistent depolarization (fasciculations followed by flaccid paralysis).
Pediatric Dosing Nuance: Infants and young children possess a larger extracellular fluid (ECF) volume distribution and require higher weight-based doses ( 2.0 mg/kg ) compared to adolescents and adults (1.0–1.5 mg/kg).
Rapid Onset & Short Duration: Onset in 30–60 seconds; duration of 5–10 minutes, making it the fastest agent for emergency airway control.
Contraindications: (The FDA boxed warning concerns hyperkalemic cardiac arrest in children with undiagnosed myopathies.)
Major thermal burns >24–48 hours old (extrajunctional acetylcholine receptor upregulation causes lethal potassium efflux).
Extensive crush injury, denervating spinal cord trauma, or stroke >48 hours old.
Pre-existing hyperkalemia (use extra caution in renal failure, where potassium may already be high).
Known or suspected muscular dystrophies (e.g., Duchenne/Becker), where administration triggers rhabdomyolysis, catastrophic hyperkalemia, and cardiac arrest.
Personal or family history of malignant hyperthermia.
Rocuronium (1.0–1.2 mg/kg IV/IO for RSI)
A monoquaternary aminosteroid non-depolarizing NMBA that competitively antagonizes nicotinic acetylcholine receptors without triggering depolarization.
RSI Dosing: While 0.6 mg/kg produces paralysis in 90–120 seconds, the standard transport RSI dose is 1.0 to 1.2 mg/kg , which shortens onset time to 45–60 seconds (comparable to succinylcholine).
Duration: 45 to 90 minutes. Because rocuronium has a prolonged duration, the transport crew must be fully prepared to manage a failed airway throughout the entire flight.
Reversal: Directly encapsulated and neutralized by sugammadex .
Vecuronium (0.1 mg/kg IV/IO)
Non-depolarizing aminosteroid with an onset of 2–3 minutes and duration of 30–45 minutes. Primarily utilized for post-intubation maintenance paralysis rather than rapid induction.
Acute Complication: Fentanyl-Induced Rigid Chest Syndrome
A critical, life-threatening adverse event frequently tested on the C-NPT exam is wooden chest syndrome (fentanyl-induced chest wall rigidity). This phenomenon occurs when fentanyl is administered as a rapid intravenous push, particularly at high doses (>3–5 mcg/kg) or in neonates and young infants.
Pathophysiology: Centrally mediated stimulation of striatal GABA and mu-opioid pathways produces intense hypertonus of the intercostal, diaphragm, abdominal, and laryngeal muscles.
Clinical Presentation: Within seconds of injection, the patient develops sudden, board-like chest wall rigidity, jaw clenching, and vocal cord adduction. The transport clinician becomes completely unable to ventilate the patient with a bag-valve-mask; peak inspiratory pressures spike to maximum, and the chest will not rise, followed by acute hypoxemic cyanosis and bradycardia.
Immediate Management:
Option A (Definitive Paralysis): Administer a rapid-acting neuromuscular blocker ( rocuronium 1.0–1.2 mg/kg or succinylcholine if not contraindicated). Paralysis immediately relaxes the skeletal and laryngeal musculature, permitting immediate bag-mask ventilation and tracheal intubation.
Option B (Opioid Reversal): Administer Naloxone (0.01–0.1 mg/kg IV/IO). Naloxone displaces the opioid and resolves the rigidity within 1–2 minutes, but completely reverses analgesia and sedation.
Pain Assessment and Non-Pharmacologic Comfort
NCC lists pain management first under pharmacology. Pain in transport is often undertreated because children cannot report it and monitors mask it.
Neonates: Validated tools include NIPS (Neonatal Infant Pain Scale), PIPP-R (Premature Infant Pain Profile–Revised), and N-PASS (Neonatal Pain, Agitation, and Sedation Scale), which also scores sedation in ventilated infants.
Preverbal and nonverbal children: The FLACC scale (Face, Legs, Activity, Cry, Consolability).
Children about 3–7 years and older: Faces scales such as Wong-Baker FACES or the Faces Pain Scale–Revised. Older children and adolescents can use a 0–10 numeric scale .
Sedated or paralyzed patients: Watch for tachycardia, hypertension, tearing, and rising ICP. Paralysis removes behavioral signs, so analgesia must be scheduled rather than given only in response to visible distress.
Non-pharmacologic measures are part of treatment: swaddling and facilitated tucking, non-nutritive sucking with oral sucrose for brief neonatal procedures (per unit protocol), skin-to-skin contact or parental presence when possible, distraction for older children, and minimal handling and noise.
Analgesic options beyond opioids include acetaminophen (oral, rectal, or IV), ketamine (IV or intranasal), and local or topical anesthetics (for example, lidocaine for chest tubes and for IO insertion in conscious patients). NSAIDs are avoided with coagulopathy, kidney injury, and in some neonatal settings. Opioids remain the mainstay for severe pain and for ventilated patients.
Post-Intubation Maintenance Sedation & Pharmacological Reversal
Once an artificial airway is secured, the transport team must institute a continuous maintenance sedation protocol. Inadequate sedation leads to accidental extubation, ventilator dyssynchrony, elevated ICP, and intense psychological trauma, while over-sedation causes hemodynamic instability and prolonged recovery.
Continuous Maintenance Infusions
Fentanyl: 1–4 mcg/kg/hr continuous IV infusion. Provides excellent analgesia with stable hemodynamics.
Morphine: 10–40 mcg/kg/hr IV. Excellent for cardiac patients; produces modest venodilation that can lower preload beneficially in pulmonary edema, but risks histamine release and hypotension in hypovolemia.
Dexmedetomidine (Precedex): 0.2–1.4 mcg/kg/hr IV. Selective alpha-2 agonist delivering 'cooperative' sedation without significant respiratory depression. Ideal for non-invasive ventilation or post-extubation transport; can cause bradycardia and biphasic blood pressure changes.
Midazolam: 0.05–0.2 mg/kg/hr IV. Provides reliable amnesia and anxiolysis; should be titrated carefully with opioids to prevent synergistic vasodilation.
Pharmacological Reversal Protocols
Naloxone (0.01–0.1 mg/kg IV/IO, max 2.0 mg): Pure mu-opioid competitive antagonist. In transport, titrate in small increments (0.005–0.01 mg/kg) when reversing unintended respiratory depression to preserve analgesia, unless patient is in full respiratory arrest.
Flumazenil (0.01 mg/kg, max 0.2 mg): Specific benzodiazepine antagonist. Caution: Contraindicated in patients with known seizure disorders, chronic benzodiazepine therapy, or tricyclic antidepressant ingestion due to the risk of intractable status epilepticus.
Sugammadex: Modified gamma-cyclodextrin that selectively encapsulates rocuronium and vecuronium in plasma. Dose: 2 mg/kg for routine reversal (reappearance of T 2 T_2 T 2 on train-of-four); 4 mg/kg for deep neuromuscular block (1–2 post-tetanic twitches); 16 mg/kg for immediate emergency rescue reversal 3 minutes after a 1.2 mg/kg rocuronium RSI dose. In the U.S., pediatric labeling covers patients 2 years and older for the 2 and 4 mg/kg doses; the 16 mg/kg immediate-reversal dose comes from adult labeling.
Neostigmine (0.05 mg/kg) + Glycopyrrolate (0.01 mg/kg): Traditional reversal for non-depolarizing blockers; acetylcholinesterase inhibition combined with an anticholinergic to prevent muscarinic bradycardia.